Mr. Francois Roberge reports

LSL PHARMA GROUP ANNOUNCES THE SEMI-ANNUAL INTEREST PAYMENT ON THE CONVERTIBLE DEBENTURES LISTED AS LSL.DB

The semi-annual interest payment on LSL Pharma Group Inc.'s outstanding unsecured convertible debentures listed on the TSX Venture Exchange under symbol LSL.DB will be made on April 30, 2025. The record date for the payment of interest on the debentures is April 21, 2025. The corporation will pay to each debentureholder of record an amount of $54.55 per $1,000 principal amount of debentures, which represents accrued interest payable from Oct. 31, 2024, to April 29, 2025, inclusively.

The corporation also confirms that, as a result of the acquisition of Dermolab Pharma Ltd. announced on Dec. 18, 2024, the corporation has achieved a business objective as defined in the debenture indenture for the recalculation of the interest rate. The Dermolab acquisition represents an acquisition of a business that: (a) complements the corporation's existing product offering and/or will create synergies with the corporation's existing business operations; and (b) generated a minimum of $5-million in revenue during the last-12-month period preceding the acquisition. Consequently, the annual interest rate shall be reduced by 1 per cent from 11 per cent to 10 per cent per annum, effective April 30, 2025, and the next interest payment to take place on Oct. 31, 2025, will be for an amount of $50.41 per $1,000 principal amount of debentures. The interest rate will remain at 10 per cent until maturity of the debentures unless any other business objectives are achieved, which could reduce the interest rate further.

For additional details regarding the debentures, please refer to the debenture indenture dated Nov. 1, 2023, which is available under LSL Pharma's issuer profile on SEDAR+.

About LSL Pharma Group INC.

LSL Pharma Group is a Canadian integrated pharmaceutical company specializing in the development, manufacturing and marketing of high-quality sterile ophthalmic pharmaceuticals as well as cosmetics, pharmaceuticals and natural health products in solid, semi-solid and liquid forms.